JTV 519
Alternative Names: JTV-519; K201 - Merck; K201 - SequelLatest Information Update: 21 Oct 2024
Price :
$50 *
At a glance
- Originator Aetas Pharma; Japan Tobacco
- Developer Aetas Pharma; Sequel Pharmaceuticals
- Class Small molecules; Thiazepines
- Mechanism of Action Calcium channel antagonists; Potassium channel antagonists; Protein kinase C stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Heart failure
- Research Arrhythmias; Diabetes mellitus; Kidney disorders
- Discontinued Atrial fibrillation; Cancer; Myocardial infarction
Most Recent Events
- 21 Oct 2024 JTV 519 is still in preclinical development for Heart failure in Japan (IV) (Aetas Pharma Pipeline, October 2024)
- 21 Oct 2024 Early research in Arrhythmias in Japan (unspecified route) prior to October 2024 (Aetas Pharma Pipeline, October 2024)
- 21 Oct 2024 Early research in Diabetes mellitus in Japan (unspecified route) prior to October 2024 (Aetas Pharma Pipeline, October 2024)